Evaluation of Semen Self-Sampling Yield Predictors and CTC Isolation by Multi-Color Flow Cytometry for Liquid Biopsy of Localized Prostate Cancer

Review Oncology

Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis

Sabareeswaran Krishnan et al.

Summary: Metabolite biomarkers in blood and urine may serve as promising tools for the early diagnosis of prostate cancer.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer

Alexey S. S. Rzhevskiy et al.

Summary: Currently, there is a lack of sensitive and specific methods for the detection and prognosis of early stage prostate cancer. Liquid biopsy, a novel technique that extracts biomarkers such as circulating tumor cells, exosomal miRNAs, and circulating DNAs, has been investigated as a supplement or alternative to the traditional screening methods for prostate cancer.

BIOMEDICINES (2022)

Add to Collection

Article Multidisciplinary Sciences

Impact of active surveillance for prostate cancer on the risk of depression and anxiety

Davidson Sypre et al.

Summary: Active surveillance is a standard treatment option for low risk localized prostate cancer. This study found that patients managed with active surveillance do not report more anxiety or depressive symptoms compared to patients managed with curative treatment.

SCIENTIFIC REPORTS (2022)

Add to Collection

Letter Oncology

Re: Stefano Fanti, Alberto Briganti, Louise Emmett, et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022;5:530-6 Extended Use of PSMA PET/CT in Candidates for Focal Therapy

Egesta Lopci et al.

EUROPEAN UROLOGY ONCOLOGY (2022)

Add to Collection

Review Urology & Nephrology

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Nicolas Mottet et al.

Summary: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on screening, diagnosis, and treatment of localized prostate cancer summarize the most recent recommendations for clinical practice, including risk-adapted strategies, medical imaging utilization, biopsy techniques, patient classification, and treatment options. Recommendations include consideration of moderate hypofractionation for intermediate-risk patients and a combination of local treatment with long-term hormonal therapy for cN1 PCa patients.

EUROPEAN UROLOGY (2021)

Add to Collection

Review Urology & Nephrology

Ejaculation Disorders in Male Patients with Cancer: A Systematic Review and Meta-Analysis of Prevalence

Damiano Pizzol et al.

Summary: This systematic review and meta-analysis found a high prevalence of ejaculatory dysfunction and erectile dysfunction in cancer patients across different cancer sites and treatment types. Prospective studies on these complications after various cancer treatments are needed for further understanding and management.

JOURNAL OF UROLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management

Wojciech A. Cieslikowski et al.

Summary: CTC enumeration shows promise in the management of prostate cancer, particularly in monitoring treatment outcomes. However, most data come from randomized studies of anticancer agents and may not directly translate into clinical practice. Further research is needed to understand the role of CTC in early-stage prostate cancer.

BIOMEDICINES (2021)

Add to Collection

Review Urology & Nephrology

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis

Andrea Mari et al.

Summary: Alfuzosin is an effective drug for treating LUTS/BPH with lower rates of sexual disorders compared to other alpha-blockers. It is safe with low adverse events in combination therapy with other medications and in patients with cardiovascular conditions. Alfuzosin has shown to be effective and safe in various clinical trials.

THERAPEUTIC ADVANCES IN UROLOGY (2021)

Add to Collection

Review Urology & Nephrology